International audienceBiomarker; Prognostic Factor; Anti-TNF Agent; Response to Therapy; TAILORIX. We investigated pharmacodynamic features of infliximab and radiological healing
Objectives: Crohn’s disease is a chronic, relapsing inflammatory disease of the gastro-intestinal tr...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn’s di...
BACKGROUND & AIMS: Biomarker; Prognostic Factor; Anti-TNF Agent; Response to Therapy; TAILORIX. We i...
Background & Aims: Higher infliximab trough levels are associated with clinical and endoscopic remis...
peer reviewedBACKGROUND & AIMS: Biomarker; Prognostic Factor; Anti-TNF Agent; Response to Therapy; T...
Background/Aims: Controlled studies in humans have shown the role of antibodies to tumor necrosis fa...
Background/AimsDecreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are as...
This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disea...
BACKGROUND AND AIMS: Anti TNF therapy induces mucosal healing in patients with Crohn's disease, but ...
BACKGROUND: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn’s di...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Objectives: Crohn’s disease is a chronic, relapsing inflammatory disease of the gastro-intestinal tr...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn’s di...
BACKGROUND & AIMS: Biomarker; Prognostic Factor; Anti-TNF Agent; Response to Therapy; TAILORIX. We i...
Background & Aims: Higher infliximab trough levels are associated with clinical and endoscopic remis...
peer reviewedBACKGROUND & AIMS: Biomarker; Prognostic Factor; Anti-TNF Agent; Response to Therapy; T...
Background/Aims: Controlled studies in humans have shown the role of antibodies to tumor necrosis fa...
Background/AimsDecreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are as...
This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disea...
BACKGROUND AND AIMS: Anti TNF therapy induces mucosal healing in patients with Crohn's disease, but ...
BACKGROUND: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn’s di...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Objectives: Crohn’s disease is a chronic, relapsing inflammatory disease of the gastro-intestinal tr...
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TN...
Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn’s di...